SCHEMBL1448706

SCHEMBL1448706

COC(=O)c1c([N+](=O)[O-])ccc(F)c1CC(NC=O)OC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
MAPT P10636 4/20 0.34
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
KMT2A Q03164 2/20 0.33
ERN1 O75460 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 4/20 0.32
TDP1 Q9NUW8 2/20 0.32
ABCC4 O15439 2/20 0.32
CACNA1F O60840 2/20 0.32
ABCB11 O95342 2/20 0.32
LMNA P02545 2/20 0.32
CYP1A2 P05177 2/20 0.32
ADORA3 P0DMS8 2/20 0.32
ADORA2A P29274 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1448708 0.78 LMNA (0.35) ABL1BCRMAPTSMN1; SMN2KMT2A
SCHEMBL1448819 0.77 ABL1 (0.39) ABL1BCRMAPTSMN1; SMN2KMT2A
SCHEMBL1448192 0.76 TDP1 (0.40) ABL1BCRMAPTSMN1; SMN2KMT2A
SCHEMBL1448737 0.76 KMT2A (0.37) ABL1BCRMAPTSMN1; SMN2KMT2A
SCHEMBL1449060 0.74 CYP4A11 (0.40) ABL1BCRMAPTSMN1; SMN2KMT2A
SCHEMBL1448297 0.74 FBP1 (0.43) KMT2AMEN1ALDH1A1LMNA
SCHEMBL30395006 0.72 SMN1; SMN2 (0.42) MAPTRAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL1448702 0.72 SMN1; SMN2 (0.35) ABL1BCRMAPTRAB9ANPC1
SCHEMBL1448325 0.71 KMT2A (0.44) MAPTSMN1; SMN2KMT2AMEN1GAA
SCHEMBL1448986 0.70 SMN1; SMN2 (0.41) ABL1BCRMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1784399-B1 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2011-06-15 EP disclosed
US-7910585-B2 Pyrimidine derivatives NOVARTIS AG (CH) 2011-03-22 US disclosed
US-20080293708-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1784399-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP disclosed
WO-2006021457-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293708-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS ABL1 751/4885BCR 1255/4885MAPT 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.